Evidence-based dermatology

Cutis

Volumn 75, Issue 3 SUPPL., 2005, Pages 8-12

  Margolis, David J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; AZELAIC ACID; AZITHROMYCIN; CLARITHROMYCIN; CLINDAMYCIN; DOXYCYCLINE; ISOTRETINOIN; LYMECYCLINE; METRONIDAZOLE; RETINOIC ACID; SULFACETAMIDE; SULFUR; TETRACYCLINE;

CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC TEST; EVIDENCE BASED MEDICINE; HUMAN; METHODOLOGY; PHYSICIAN; ROSACEA; SKIN DISEASE; SKIN IRRITATION; VALIDATION PROCESS;

ANTI-INFECTIVE AGENTS; DERMATOLOGIC AGENTS; DERMATOLOGY; EVIDENCE-BASED MEDICINE; HUMANS; ROSACEA;

EID: 17144418587     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (39)

1. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence-based medicine: what it is and what it isn't. BMJ. 1996;312:71-72.
2. Guyatt GH, Haynes RB, Jaeschke RZ, et al. Users' guides to the medical literature, XXV: evidence-based medicine: principles for applying the users' guides to patient care. JAMA. 2000;284:1290-1296.
3. Williams H, Bigby M. The rationale for evidence-based dermatology. In: Williams H, ed. Evidence-Based Dermatology. London, UK: BMJ Books; 2003:9-16.
4. Bigby M. Finding the best evidence. In: Williams H, ed. Evidence-Based Dermatology. London, UK: BMJ Books; 2003:38-43.
5. Spilker B. Establishing the overall approach to a clinical trial. In: Guide to Clinical Trials. New York, NY: Raven Press; 1991:7-9.
6. Spilker B. Classification and description of phase I, II, and III clinical trial designs. In: Guide to Clinical Trials. New York, NY: Raven Press; 1991:27-43.
7. Spilker B. Classification and description of phase IV post-marketing study designs. In: Guide to Clinical Trials. New York, NY: Raven Press; 1991:44-58.
8. Spilker B. Meta-analysis. In: Guide to Clinical Trials. New York, NY: Raven Press; 1991:793-800.
9. Rebora A. Papulopustular rosacea. In: Williams H, ed. Evidence-Based Dermatology. London, UK: BMJ Books; 2003:115-124.
10. Marks R, Ellis J. Comparative effectiveness of tetracycline and ampicillin in rosacea. a controlled trial. Lancet. 1971;2:1049-1052.
11. Nielsen PG. A double-blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. Br J Dermatol. 1983;109:63-65.
12. Sneddon IB. A clinical trial of tetracycline in rosacea. Br J Dermatol. 1966;78:649-652.
13. Nielsen PG. Treatment of rosacea with 1% metronidazole cream. a double-blind study. Br J Dermatol. 1983;108:327-332.
14. Pye RJ, Burton JL. Treatment of rosacea by metronidazole. Lancet. 1976;1:1211-1212.
15. Guilhou JJ, Guilhou E, Malbos S, et al. Traitement de la rosacée par le métronidazole. Ann Dermatol Venereol. 1979;106:127-129.
16. Gamborg-Nielsen P. Metronidazole treatment in rosacea. Int J Dermatol. 1988;27:1-5.
17. McClellan KJ, Noble S. Topical metronidazole. a review of its use in rosacea. Am J Clin Dermatol. 2000;1:191-199.
18. Bleicher PA, Charles JH, Sober AJ. Topical metronidazole therapy for rosacea. Arch Dermatol. 1987;123:609-614.
19. Bjerke JR, Nyfors A, Austad J, et al. Metronidazole (Elyzol) 1% cream v placebo cream in the treatment of rosacea. Clin Trials J. 1989;26:187-194.
20. Bitar A, Bourgouin J, Doré N, et al. A double-blind randomised study of metronidazole (Flagyl) 1% cream in the treatment of acne rosacea. a placebo-controlled study. Drug Invest. 1990;2:242-248.
21. Breneman DL, Stewart D, Hevia O, et al. A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis. 1998;61:44-47.
22. Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol. 1998;134:679-683.
23. Jorizzo JL, Lebwohl M, Tobey RE. The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double-blind clinical trial. J Am Acad Dermatol. 1998;39:502-504.
24. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol. 1999;40:961-965.
25. Veien NK, Christiansen JV, Hjorth N, et al. Topical metronidazole in the treatment of rosacea. Cutis. 1986;38:209-210.
26. Aronson IK, Rumsfield JA, West DP, et al. Evaluation of topical metronidazole gel in acne rosacea. Drug Intell Clin Pharm. 1987;21:346-351.
27. Drake L, Leyden J, Lucky A, et al. Evaluation of topical metronidazole cream in rosacea. Poster presented at: 55th Annual Meeting of the American Academy of Dermatology; March 21-26, 1997; San Francisco, Calif. P65.
28. Espagne E, Guillaume JC, Archimbaud A, et al. Double-blind study versus excipient of 0.75% metronidazole gel in the treatment of rosacea. Ann Dermatol Venereol. 1993;120:129-133.
29. Nielsen PG. The relapse rate for rosacea after treatment with either oral tetracycline or metronidazole cream [letter]. Br J Dermatol. 1983;109:122.
30. Monk BE, Logan RA, Cook J, et al. Topical metronidazole in the treatment of rosacea. J Dermatol Treat. 1991;2:91-93.
31. Signore RJ. A pilot study of 5 percent permethrin cream versus 0.75 percent metronidazole gel in acne rosacea. Cutis. 1995;56:177-179.
32. Dreno B, Dubertret L, Naeyaert JM, et al. Comparison of the clinical efficacy and safety of metronidazole 0.75% cream with metronidazole 0.75% gel in the treatment of rosacea. J Eur Acad Dermatol Venereol. 1998;11:S272-S273. Abstract P373.
33. Guillet B, Rostain E, Powell F, et al. Metronidazole 0.75% gel and lotion are both effective in the treatment of rosacea [abstract]. J Eur Acad Dermatol Venereol. 1999;2(suppl 2):S145. Abstract P-015.
34. Bjerke R, Fyrand O, Graupe K. Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulopustular rosacea. Acta Derm Venereol. 1999;79:456-459.
35. Blom I, Hornmark AM. Topical treatment with sulfur 10 percent for rosacea. Acta Derm Venereol. 1984;64:358-359.
36. Sauder DN, Miller R, Gratton D, et al. The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double-blind study. J Dermatol Treat. 1997;8:79-85.
37. Wilkin JK, Dewitt S. Treatment of rosacea: topical clindamycin versus oral tetracycline. Int J Dermatol. 1993;32:65-67.
38. Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol. 1994;130:319-324.
39. Sackett DL. How to read clinical journals, V: to distinguish useful from useless or even harmful therapy. Can Med Assoc J. 1981;124:1156-1162.